arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

GILEAD SCIENCES, INC.

GILD
$151.40 ▼ -1.28 (-0.84%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
75 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

GILEAD SCIENCES, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $188.2B
Dividend Yield 0.54%
Revenue Growth 10.2%
Op. Margin -133.2%
ROIC -27.9%
FCF / Share $2.76
Trailing P/E
Price / Book 15.9x
FCF Yield 1.8%
Debt / Equity 2.22
info Valuation on last close. End-of-day price, Sep 23, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$7.80B
↑ +10.2%
Net Income Profit after all expenses
$-10.50B
↓ -619.3%
Operating Margin Operating profit as % of sales
-133.2%
↓ -458.5% 90th
FCF / Share Free cash flow per share
$2.76
↑ +41.3%
Long-Term Debt Long-term obligations
$26.25B
↑ +18.4%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
91
Returns
95
Financial Health
54
Cash Quality
70

Dividend History

Dividend / share · sourced from SEC filings
$3.16 Latest / share
+2.6% YoY

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 75 quarters